R. Alexander

发表

Evaluation of antidepressant properties of the p38 MAP kinase inhibitor losmapimod (GW856553) in Major Depressive Disorder: Results from two randomised, placebo-controlled, double-blind, multicentre studies using a Bayesian approach

E. Merlo-Pich, S. Zamuner, E. Ratti, 2014, Journal of psychopharmacology.

Bayesian approach multicentreMajor Depressive Disorder : Results from two randomised , placebo-controlled , double-blind , Evaluation of antidepressant properties of the p 38 MAP kinase inhibitor losmapimod

E. Merlo-Pich, S. Zamuner, E. Ratti, 2014 .

Prediction and Modeling of Effects on the QTc Interval for Clinical Safety Margin Assessment, Based on Single-Ascending-Dose Study Data with AZD3839

Michael D B Swedberg, C. Pollard, M. Bridgland-Taylor, 2014, The Journal of Pharmacology and Experimental Therapeutics.

EFFICACY OF VESTIPITANT IN PRIMARY INSOMNIA

H. Danker-Hopfe, L. Squassante, E. Merlo-Pich, 2013 .

Orexin 2 receptor–selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients

C. Davies, E. Mignot, Y. Dauvilliers, 2022, Proceedings of the National Academy of Sciences of the United States of America.

Adjudicating Mild Cognitive Impairment Due to Alzheimer’s Disease as a Novel Endpoint Event in the TOMMORROW Prevention Clinical Trial

L. Schneider, D. Bennett, Y. Stern, 2021, The Journal of Prevention of Alzheimer's Disease.

Computerized cognitive remediation training for schizophrenia: An open label, multi-site, multinational methodology study

S. Kapur, B. Wexler, P. Maruff, 2012, Schizophrenia Research.

Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial

Jennifer G. Robinson, Alex A. Knopman, D. Rujescu, 2021, The Lancet Neurology.

Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials

K. Krishnan, J. Modell, S. Zamuner, 2012, Journal of psychopharmacology.

Orexin 2 receptor‐selective agonist danavorexton (TAK‐925) promotes wakefulness in non‐human primates and healthy individuals

Yaming Hang, H. Faessel, H. Yukitake, 2023, Journal of sleep research.

Results of a phase 1, 4-period crossover, placebo-controlled, randomized, single dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-925, a novel orexin 2 receptor agonist, in sleep-deprived healthy adults, utilizing modafinil as an active comparator

H. Faessel, R. Alexander, L. Rosen, 2019 .

Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist

G. Nucci, L. Squassante, P. Bettica, 2012, Journal of psychopharmacology.

TOMMORROW: RESULTS FROM A PHASE 3 TRIAL TO DELAY THE ONSET OF MCI DUE TO AD AND QUALIFY A GENETIC BIOMARKER ALGORITHM

K. Welsh-Bohmer, A. Saunders, J. Burke, 2019, Alzheimer's & Dementia.

Population pharmacokinetic and pharmacodynamic analysis of plasma Aβ40 and Aβ42 following single oral doses of the BACE1 inhibitor AZD3839 to healthy volunteers

Chi-Ming Lee, E. Sparve, J. Fälting, 2014, Clinical pharmacology in drug development.

Biomarkers for response in major depression: comparing paroxetine and venlafaxine from two randomised placebo-controlled clinical studies

E. Domenici, L. Carboni, M. Filosi, 2019, Translational Psychiatry.

Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies

M. Fava, E. Rabiner, P. Bettica, 2013, Journal of psychopharmacology.

Efficacy of vestipitant, a neurokinin-1 receptor antagonist, in primary insomnia.

H. Danker-Hopfe, L. Squassante, E. Merlo-Pich, 2013, Sleep.

Tolerability, pharmacokinetics and night-time effects on postural sway and critical flicker fusion of gaboxadol and zolpidem in elderly subjects.

J. McCrea, N. Calder, M. Murphy, 2009, British journal of clinical pharmacology.

Folate metabolism biomarkers from two randomised placebo-controlled clinical studies with paroxetine and venlafaxine

E. Domenici, L. Carboni, B. Delafont, 2020, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

A Phase 1 single ascending dose study of a novel orexin 2 receptor agonist, TAK-925, in healthy volunteers (HV) and subjects with narcolepsy type 1 (NT1) to assess safety, tolerability, pharmacokinetics, and pharmacodynamic outcomes

S. Touno, H. Faessel, R. Alexander, 2019 .

MONITORING THE SOLUBLE AMYLOID PRECURSOR PROTEIN ALPHA (SAPPA) AND BETA (SAPPB) FRAGMENTS IN PLASMA AND CSF FROM HEALTHY INDIVIDUALS TREATED WITH BACE INHIBITOR AZD3293 IN A MULTIPLE ASCENDING DOSE STUDY: PHARMACOKINETIC AND PHARMACODYNAMIC CORRELATE

S. Haeberlein, H. Zetterberg, H. Salter, 2014, Alzheimer's & Dementia.

AZD3293 A novel BACE1 inhibitor: safety, tolerability, and effects on plasma and CSF Aβ peptides following single- and multiple-dose administration

L. Ereshefsky, S. Budd, K. Elsby, 2014, Neurobiology of Aging.

Tolerability, pharmacokinetics and night-time effects on postural sway and critical flicker fusion of gaboxadol and zolpidem in elderly subjects.

J. McCrea, N. Calder, J. Boyle, 2009, British journal of clinical pharmacology.